HIV-1 Resistance (Integrase)
| Category | Virology |
|---|---|
| Test background |
This HIV-1 Integrase Genotype test is designed to detect mutations associated with resistance to raltegravir dolutegravir or elvitegravir, the only FDA-approved HIV integrase strand transfer inhibitors (INSTIs) currently available. These drugs represent a class of antiretrovirals that inhibit the catalytic activity of integrase and thereby prevent formation of the HIV provirus required for viral propagation. Integrase resistance testing is recommended for patients experiencing virologic failure while taking these integrase inhibitors. It can also be considered as a supplement to standard baseline genotypic resistance testing if transmitted resistance to either drug is suspected. |
| Clinical Indications |
Baseline and/or when failing therapy |
| Reference range | Contact Laboratory |
| Sample & container required | EDTA whole blood |
| Sample volume | 10mL |
| Turnaround time | 14 days |
| Notes | Must have quantifiable HIV-1 viral load. This assay has changed to the Vela NGS assay is currently awaiting UKAS accreditation. |